Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag Publisert: 10.05.2023 Navamedic ASA: Invitation to 2023 1st quarter presentation Publisert: 08.05.2023 Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag Publisert: 28.04.2023 Navamedic ASA: Annual Report for 2022 Publisert: 28.04.2023 Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag Publisert: 26.04.2023 Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1 Publisert: 25.04.2023 FørsteForrige2122232425NesteSiste
Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag Publisert: 10.05.2023
Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag Publisert: 28.04.2023
Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag Publisert: 26.04.2023
Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1 Publisert: 25.04.2023